There are currently 928 clinical trials in Durham, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Duke University Medical Center, Duke University, Duke Comprehensive Cancer Center and Duke University Health System. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT05233397
Recruiting
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
05/23/2025
Locations: Duke Children's Hospital, Durham, North Carolina
Conditions: Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Register for Updates
SenseToKnow Autism Screening Device Validation Study
NCT05874466
Recruiting
This is a pivotal, prospective, double-blind, study to evaluate the sensitivity and specificity of the SenseToKnow app for the detection of autism spectrum disorder in children 16-36 months of age.
Gender:
ALL
Ages:
Between 16 months and 36 months
Trial Updated:
05/23/2025
Locations: Duke University, Durham, North Carolina
Conditions: Autism, Autism Spectrum Disorder
Register for Updates
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
NCT06297590
Recruiting
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive L... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
05/23/2025
Locations: Duke University, Durham, North Carolina
Conditions: Alzheimer Disease
Register for Updates
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
NCT04896697
Recruiting
This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Advanced Solid Tumor
Register for Updates
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
NCT04985903
Recruiting
The investigators propose to conduct a combined intervention that pairs SMS smoking cessation messages for patients with individualized training for OB clinicians to improve quit rates among pregnant smoking. The aim is to determine the effect of the intervention versus control on smoking cessation outcomes on patient smoking cessation. The investigators will recruit patients at their first OB visit who report smoking at Duke and Pitt. Patients in both the control and intervention arm will recei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Durham OB, Durham, North Carolina
Conditions: Smoking Cessation, Pregnancy, Communication Research
Register for Updates
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
NCT05465174
Recruiting
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
05/22/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Register for Updates
Cochlear Implants in Young Children With SSD
NCT05775367
Recruiting
The goal of this clinical trial is to investigate the safety and effectiveness of cochlear implantation in infants and toddlers with single-sided deafness. The main questions it aims to answer are: * Are cochlear implants an effective treatment of single-sided deafness in infants and toddlers? * Are cochlear implants a safe treatment for single-sided deafness in infants and toddlers? Participants will receive a cochlear implant and be followed until they are five years old. During those five... Read More
Gender:
ALL
Ages:
Between 7 months and 71 months
Trial Updated:
05/22/2025
Locations: The Children's Cochlear Implant Center at UNC, Durham, North Carolina
Conditions: Single Sided Deafness, Unilateral Deafness, Hearing Loss, Unilateral, Hearing Loss, Congenital Hearing Loss, Deafness One Ear
Register for Updates
Preschool Attention and Sleep Support (PASS)
NCT05862727
Recruiting
This study will be investigating two telehealth interventions for preschoolers with ADHD. The study is divided into two Aims. During Aim 1, caregivers of preschoolers with attention concerns, pediatric behavioral health professionals, and pediatric primary care providers will take part in two virtual focus groups to provide their perspective on ways to improve the telehealth intervention being evaluated.
Gender:
ALL
Ages:
Between 3 years and 5 years
Trial Updated:
05/22/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: ADHD, Psychiatric Health
Register for Updates
Eye Plaque Brachytherapy for Ocular Melanoma
NCT06432660
Recruiting
This prospective registry study will evaluate doses utilized in eye plaque brachytherapy for the treatment of ocular melanoma and their associated outcomes. The goal of this study is to evaluate if lower doses of radiation can maintain high local control rates while minimizing the toxicities related to radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Ocular Melanoma
Register for Updates
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
NCT05832229
Recruiting
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: Duke Liver Center, Durham, North Carolina
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Register for Updates
Preserving Physical Function in Older Adults With Cancer: Impact of an Optimizing Nutrition Intervention Applied Before and After Surgery
NCT05912257
Recruiting
In this pragmatic clinical trial, the investigators will study older Veterans approaching surgery for gastrointestinal or genitourinary cancer who are at high risk for a marked decline in their physical function. The investigators will test a multi-targeted nutrition regimen high in protein and other key nutrients and including resistance exercise, administered 8 weeks prior to surgery and for 24 weeks after discharge from surgery, with the goal of protecting physical function and improving phys... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/21/2025
Locations: Durham VA Medical Center, Durham, NC, Durham, North Carolina
Conditions: Cancer
Register for Updates
Platform Clinical Study for Conquering Scleroderma
NCT06195072
Recruiting
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Register for Updates